Study M781
Study name | Homorogan C 2021 |
Title | Untargeted plasma metabolomic profiling in patients with major depressive disorder using ultra-high performance liquid chromatography coupled with mass spectrometry |
Overall design | The aims of this study were to investigate possible differences in metabolites levels between patients with major depressive disorder (MDD) before treatment and healthy volunteers to assess their potential diagnostic biomarker role for MDD detection, and to analyse the antidepressant effect of escitalopram by comparing the metabolome of the same patients at baseline, and after a 12-week follow-up period, with escitalopram antidepressant treatment. A total number of 22 participants were enrolled in this study, out of which 11 were patients suffering from MDD (MDD group), and 11 were healthy subjects (control group). Untargeted metabolomic profiling was performed from plasma samples of MDD patients, before and after treatment with escitalopram, and from plasma samples of healthy volunteers, by ultra-high performance liquid chromatography coupled with electrospray ionization-quadrupole-time of flight-mass spectrometry. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV-TR diagnosed MDD |
Sample size | 22 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: ThermoFisher Scientific UHPLC Ultimate 3000 instrument; |
PMID | |
DOI | |
Citation | Homorogan C, Nitusca D, Enatescu V, et al. Untargeted plasma metabolomic profiling in patients with major depressive disorder using ultra-high performance liquid chromatography coupled with mass spectrometry. Metabolites. 2021 Jul 20;11(7):466. |
Metabolite |
